IntrinsicIntrinsic
← All summaries

BRUKER CORP

BRKRP
Financials & Chart →

Business Summary

Bruker Corporation is a developer, manufacturer, and distributor of high-performance scientific instruments and analytical and diagnostic solutions that enable customers to explore life and materials at microscopic, molecular, and cellular levels. The company's technology platforms include magnetic resonance, mass spectrometry, gas and liquid chromatography, X-ray, microscopy, metrology, and molecular spectroscopy technologies. Bruker serves a diverse array of customers in life and materials science research, biopharmaceuticals, applied markets, microbiology, in-vitro diagnostics, and nanotechnology. The company maintains major technical and manufacturing centers in Europe and North America and has sales offices located throughout the world.

Bruker operates in multiple highly competitive markets. The company's significant competitors by segment include: for BSI BioSpin, JEOL, QOne Instruments, Quad, Ciqtek, Magritek, Nanalysis, and Oxford Instruments in magnetic resonance spectrometers, and PerkinElmer Inc., Mediso, Trifoil, and MR Solutions in preclinical imaging; for BSI CALID, Danaher, Agilent, GE-Healthcare, Waters, Thermo Fisher Scientific, Shimadzu, Hitachi, and JEOL in mass spectrometry, Biomerieux in microbiology, and Smiths Detection in CBRNE detection; for BSI NANO, Rigaku, Oxford Instruments, Agilent, Thermo Fisher Scientific, Ametek's Spectro and Edax divisions, PANalytical, Park Systems, Olympus, Nikon, Zeiss, 10x Genomics, Thorlabs, Bio-Techne, and Danaher's Leica business; and for BEST, Western Superconducting Technologies Co., Ltd., Luvata, and Jastec Co., Ltd. in low temperature superconducting materials. Bruker believes the principal competitive factors in its markets are technology-based applications expertise, product specifications, functionality, reliability, marketing expertise, distribution capability, proprietary patent portfolios, and cost effectiveness.

Bruker generates revenue through the development, manufacture, and distribution of high-performance scientific instruments and analytical and diagnostic solutions. The company's revenue mix includes product revenue and service and other revenue. For the year ended December 31, 2025, product revenue was $2,766.4 million and service and other revenue was $670.1 million . The company sells through direct sales forces throughout North America, Europe, China, Japan, and elsewhere in the Asia Pacific region, and in certain countries in Africa and South America, as well as through indirect sales channels including international distributors and independent sales representatives. The sales cycle varies by product, typically three to twenty-four months for academic and high-end research products, two weeks to six months for industrial products, four to twelve months for low temperature superconducting materials, and more than one year for high-end NMR and superconducting devices.

Bruker is organized into four reportable segments: BSI BioSpin, BSI CALID, BSI NANO, and BEST. The BSI BioSpin Segment comprises divisions including Magnetic Resonance Spectroscopy, Preclinical Imaging, Biopharma and Applied, Services and Lifecycle Support, Integrated Data Solution, and Automation. Its instruments are based on NMR, EPR, MRI, MPI, PET, SPECT, CT, BLI, FLI, and automation technologies. The BSI CALID Segment comprises divisions including Bruker Life Sciences Mass Spectrometry, Bruker Applied Mass Spectrometry, Bruker Microbiology and Infection Diagnostics, Bruker Optics, and the Bruker Detection product line. Its instruments are based on MALDI-TOF, ESI-TOF, MRMS, ITMS, IMS, GC-MS, DART-MS, LC-MS, FT-IR, NIR, PCR, Raman, and QCL IR technologies. The BSI NANO Segment comprises Bruker AXS, Bruker Nano Surfaces and Metrology, Bruker Spatial Biology, the Consolidated Fluorescence Microscopy Business Unit, and the Bruker Cellular Analysis Business Unit. Its instruments are based on XRD, XRF, SC-XRD, µCT, EDS, EBSD, S-OES, CS/ONH, STEM, AFM, FM, SOM, TMT, NanoIR, Alicona, BCA, Canopy, NanoString, and Bruker Spatial Genomics technologies. The BEST Segment designs, manufactures, and distributes superconducting materials, including metallic low temperature superconductors and high temperature superconductors, for use in MRI, NMR, fusion energy research, and other applications, as well as non-superconducting high technology tools such as synchrotron and beamline instrumentation.

During 2025, Bruker continued its focus on enhancing customer relationships and driving innovation. In the BSI BioSpin Segment, the company completed two additional successful installations of 1.2 GHz NMR systems and completed certain minority investments. In the BSI CALID Segment, the company launched the MOVE-T solution for dairy markets, the VERTEX NEO R FTIR research spectrometer, and several new technologies and workflows advancing proteomics and multiomics in Mass Spectrometry, including timsOmni, timsMetabo, the timsUltra Athena Ion Processor, and the proteoElute nanoflow liquid chromatography system. The company also completed the acquisition of Recipe Chemicals + Instruments GmbH, a provider of vendor-agnostic therapeutic drug monitoring and other clinical in vitro diagnostic kits, and AST Revolution, LLC, an in vitro diagnostics company supporting rapid antimicrobial susceptibility testing. In the BSI NANO Segment, the company completed certain minority investments. In August 2025, the company announced a cost savings initiative aimed at reducing annualized costs by approximately $100 million to $120 million by the end of 2026. On September 8, 2025, the company issued 2,760,000 shares of Series A Mandatory Convertible Preferred Stock with a dividend rate of 6.375% per annum on the liquidation preference thereof, and used the proceeds to repay in full the outstanding balance in the 2019 term loan of $255.8 million and the outstanding balance in the 2024 Revolving Credit Agreement of $300 million , as well as repaid $37.6 million of the outstanding balance of the 2024 term loan due in 2027. During the year ended December 31, 2025, the company purchased a total of 200,731 shares at an aggregate cost of $10.0 million under the 2023 Repurchase Program, which expired in May 2025 and has not been renewed.

For the fiscal year ended December 31, 2025, Bruker reported total revenue of $3,436.5 million , a 2.1% increase compared to $3,366.4 million in 2024. Gross profit was $1,577.7 million with a gross profit margin of 45.9% , compared to $1,649.5 million and 49.0% in the prior year. Operating income was $68.2 million with an operating income margin of 2.0% , compared to $253.1 million and 7.5% in 2024. Net loss attributable to Bruker Corporation was $8.6 million compared to net income of $113.1 million in 2024. Net loss attributable to Bruker Corporation common shareholders was $22.5 million compared to net income of $113.1 million in 2024. Net cash provided by operating activities was $134.1 million compared to $251.3 million in 2024.

Business Outlook

Bruker's growth strategy includes expanding into high-potential markets, leveraging core strengths, and driving recurring revenue through aftermarket and connected services. In the BSI BioSpin Segment, the company continues to advance ultra-high field access with two additional successful installations of 1.2 GHz NMR systems in 2025, supporting studies in structural biology, pharmacology, and cellular biology. The company also completed certain minority investments in the BSI BioSpin and BSI NANO segments to expand technological capabilities, enter new markets, and enhance product portfolios. In the BSI CALID Segment, the company launched several new technologies and workflows advancing proteomics and multiomics in Mass Spectrometry, including timsOmni, timsMetabo, the timsUltra Athena Ion Processor, and the proteoElute nanoflow liquid chromatography system. The acquisitions of Recipe Chemicals + Instruments GmbH and AST Revolution, LLC enhance capabilities in small molecule clinical diagnostic assays and rapid antimicrobial susceptibility testing, respectively.

In August 2025, Bruker announced a cost savings initiative aimed at reducing annualized costs by approximately $100 million to $120 million by the end of 2026. This initiative was implemented with the intention to improve operating income and operating margins on a company-wide basis, with planned reductions affecting all parts of the business including supply chain, manufacturing, commercial operations, administrative functions, and research and development. The decrease in non-GAAP gross profit and gross profit margin during the year ended December 31, 2025, was driven by an increase in cost of goods sold due to higher U.S. tariffs, foreign exchange headwinds from a declining U.S. Dollar, and the overall revenue mix, partially offset by the impact of cost savings initiatives.

Bruker expects capital expenditures in 2026 to be consistent with the level of investing in 2025. The company is currently focused on integrating the businesses and assets acquired due to significant investments in 2024 and years prior. The company expects interest expense to decrease in 2026 primarily due to lower debt levels following the repayments made during 2025.

During the year ended December 31, 2025, Bruker's research and development expenses were $395.2 million , representing 11.5% of total revenue. Capital expenditures for purchases of property, plant and equipment were $90.8 million during the year ended December 31, 2025. The company's 2023 Repurchase Program, which authorized the purchase of up to $500.0 million of common stock over a two-year period, expired in May 2025 and has not been renewed. The company paid dividends to common and preferred shareholders of $32.9 million during the year ended December 31, 2025. In February 2026, the Board declared a quarterly dividend of $0.05 per share payable in April 2026.

Bruker faces several headwinds and constraints. The tariff increases adopted in 2025, and the uncertainty associated with them in global markets, have resulted in lower than anticipated bookings and revenues and contributed to reduced gross margins, operating margins, and profitability. During the year ended December 31, 2025, results of operations were adversely impacted by an increase in cost of goods sold as a result of increased tariffs. There remains substantial uncertainty regarding the duration of existing and newly announced tariffs, potential changes or pauses to such tariffs, tariff levels, and whether further additional tariffs or other retaliatory actions may be imposed. A meaningful portion of revenue is derived from U.S. academic institutions and research organizations that rely on government funding, and the current reduction in the level of funding and delay in such research funding has had a material adverse effect on the company's U.S. academic and governmental customers. Delays in the release of Chinese government stimulus spending have negatively affected sales growth into China, with revenue in China for the year ended December 31, 2025, of $475.8 million remaining flat compared to $471.2 million for the year ended December 31, 2024.

Geopolitical tensions, including the conflict between Russia and Ukraine, the conflict in the Middle East, and increased tensions between the U.S. and China, create uncertainty for global commerce. The company has experienced supply chain interruptions or increased costs as a result of general global economic conditions, including economic instability, changes to governmental policies and programs, export controls, economic sanctions, and trade restrictions. The company has also experienced an increase in inflationary pressures in many of the jurisdictions in which it operates. Foreign currency exchange rate fluctuations increased 2025 revenue by approximately $77.6 million , or 2.3% , and the company recorded net gains from currency translation adjustments of $115.1 million for the year ended December 31, 2025.

Risk Factors

Bruker faces material risks from new U.S. and reciprocal tariffs that have been imposed, which have resulted in lower than anticipated bookings and revenues and contributed to reduced gross margins, operating margins, and profitability, with an adverse impact from an increase in cost of goods sold as a result of increased tariffs during the year ended December 31, 2025. A meaningful portion of revenue is derived from U.S. academic institutions and research organizations that rely on government funding, and the current reduction in the level of funding and delay in such research funding has had a material adverse effect on the company's U.S. academic and governmental customers. Delays in the release of Chinese government stimulus spending have negatively affected sales growth into China, with revenue in China for the year ended December 31, 2025, of $475.8 million remaining flat compared to $471.2 million for the year ended December 31, 2024. The company recorded a goodwill impairment charge of $96.5 million during the year ended December 31, 2025, and additional impairment charges may be incurred if the fair value of reporting units declines below carrying value. Supply chain issues, including shortages of certain components such as microelectronic components and increased difficulties in obtaining a consistent supply of materials at stable pricing levels, have resulted and could continue to result in significant additional costs and manufacturing inefficiencies.

Management Priorities

Management's message emphasizes the company's commitment to ongoing innovation as a core element of its strategy to drive scientific research, develop new markets, enhance product and service offerings, and maintain leadership position. The company's strategic priorities include expanding into high-potential markets, leveraging core strengths, and driving recurring revenue through aftermarket and connected services. Management highlights the continued advancement of ultra-high field access with two additional successful installations of 1.2 GHz NMR systems in 2025, supporting studies in structural biology, pharmacology, and cellular biology. The company also announced a cost savings initiative in August 2025 aimed at reducing annualized costs by approximately $100 million to $120 million by the end of 2026, implemented with the intention to improve operating income and operating margins on a company-wide basis. Management acknowledges that the tariff increases adopted in 2025, and the uncertainty associated with them, have resulted in lower than anticipated bookings and revenues and contributed to reduced gross margins, operating margins, and profitability.

View Source Annual Report on SEC.gov ↗

References

  1. [1] Item 7, MD&A — Consolidated Results
  2. [2] Item 7, MD&A — Consolidated Results
  3. [3] Item 1, Business — Issuance of Series A Mandatory Convertible Preferred Stock
  4. [4] Item 1, Business — Issuance of Series A Mandatory Convertible Preferred Stock
  5. [5] Item 7, MD&A — Liquidity and Capital Resources
  6. [6] Item 7, MD&A — Liquidity and Capital Resources
  7. [7] Item 7, MD&A — Liquidity and Capital Resources
  8. [8] Item 5, Market for Registrant's Common Equity — Issuer Purchases of Securities
  9. [9] Item 5, Market for Registrant's Common Equity — Issuer Purchases of Securities
  10. [10] Item 7, MD&A — Consolidated Results
  11. [11] Item 7, MD&A — Consolidated Results
  12. [12] Item 7, MD&A — Consolidated Results
  13. [13] Item 7, MD&A — Consolidated Results
  14. [14] Item 7, MD&A — Consolidated Results
  15. [15] Item 7, MD&A — Consolidated Results
  16. [16] Item 7, MD&A — Consolidated Results
  17. [17] Item 7, MD&A — Consolidated Results
  18. [18] Item 7, MD&A — Consolidated Results
  19. [19] Item 7, MD&A — Consolidated Results
  20. [20] Item 7, MD&A — Consolidated Results
  21. [21] Item 7, MD&A — Consolidated Results
  22. [22] Item 7, MD&A — Consolidated Results
  23. [23] Item 7, MD&A — Consolidated Results
  24. [24] Item 7, MD&A — Consolidated Results
  25. [25] Item 7, MD&A — Consolidated Results
  26. [26] Item 7, MD&A — Consolidated Results
  27. [27] Item 7, MD&A — Results of Operations
  28. [28] Item 7, MD&A — Results of Operations
  29. [29] Item 7, MD&A — Results of Operations
  30. [30] Item 7, MD&A — Liquidity and Capital Resources
  31. [31] Item 5, Market for Registrant's Common Equity — Issuer Purchases of Securities
  32. [32] Item 7, MD&A — Liquidity and Capital Resources
  33. [33] Item 5, Market for Registrant's Common Equity — Dividends
  34. [34] Item 1A, Risk Factors
  35. [35] Item 1A, Risk Factors
  36. [36] Item 7A, Quantitative and Qualitative Disclosures About Market Risk
  37. [37] Item 7A, Quantitative and Qualitative Disclosures About Market Risk
  38. [38] Item 7A, Quantitative and Qualitative Disclosures About Market Risk
  39. [39] Item 1A, Risk Factors
  40. [40] Item 1A, Risk Factors
  41. [41] Item 7, MD&A — Results of Operations
  42. [42] Item 7, MD&A — Results of Operations
  43. [43] Item 8, Financial Statements — Consolidated Statements of Operations
  44. [44] Item 8, Financial Statements — Consolidated Statements of Operations
  45. [45] Item 7, MD&A — Consolidated Results
  46. [46] Item 8, Financial Statements — Consolidated Statements of Operations
  47. [47] Item 8, Financial Statements — Consolidated Statements of Operations
  48. [48] Item 8, Financial Statements — Consolidated Statements of Operations
  49. [49] Item 8, Financial Statements — Consolidated Statements of Operations
  50. [50] Item 8, Financial Statements — Consolidated Statements of Operations
  51. [51] Item 7, MD&A — Consolidated Results
  52. [52] Item 8, Financial Statements — Consolidated Statements of Operations
  53. [53] Item 7, MD&A — Consolidated Results
  54. [54] Item 8, Financial Statements — Consolidated Statements of Operations
  55. [55] Item 7, MD&A — Consolidated Results
  56. [56] Item 8, Financial Statements — Consolidated Statements of Operations
  57. [57] Item 7, MD&A — Consolidated Results
  58. [58] Item 8, Financial Statements — Consolidated Statements of Cash Flows
  59. [59] Item 8, Financial Statements — Consolidated Statements of Cash Flows
  60. [60] Item 7, MD&A — Non-GAAP Measures
  61. [61] Item 7, MD&A — Non-GAAP Measures
  62. [62] Item 7, MD&A — Results of Operations
  63. [63] Item 7, MD&A — Results of Operations
  64. [64] Item 7, MD&A — Results of Operations
  65. [65] Item 7, MD&A — Results of Operations
  66. [66] Item 7, MD&A — Results of Operations
  67. [67] Item 7, MD&A — Results of Operations
  68. [68] Item 7, MD&A — Results of Operations
  69. [69] Item 7, MD&A — Results of Operations
  70. [70] Item 7, MD&A — Results of Operations
  71. [71] Item 7, MD&A — Results of Operations
  72. [72] Item 7, MD&A — Results of Operations

Analysis on 6/8/2026